GOT1 and pancreatic neoplasm: As a KAT2 inhibitor, PF-04859989 inhibits GOT1 activity in a time- and pyridoxal-5 ′-phosphate (PLP)-dependent manner and selectively impairs pancreatic cancer cell line growth.